

Demystifying the Science Behind Targeted Treatments for Haematological Cancers

Virtual study day

Tuesday 2 February 2021

Aims:

The aim of this course, spread over two mornings, is to provide learners with a good, general understanding of the biology, genetics and behaviours of many haematological cancers. Educator, Dr Elaine Vickers, will also provide an up-to-date overview of modern systemic treatment approaches given to people with various haematological cancers. This includes CAR T cell therapy and other targeted approaches that have come through clinical trials in recent years.

Dr Vickers' goal is to explain the science that underpins each treatment. She also hopes to provide learners with a broad understanding of why treatments work well for some patients but not for others.

Elaine's presentations are full of colourful and enlightening illustrations to help learners make sense of scientific concepts. Her descriptions avoid unnecessary jargon and are pitched so that even those with a limited understanding of cell biology are able to understand.

Audience:

This content is ideal for research nurses, clinical nurse specialists, pharmacists and clinical trials coordinators. It may also be of interest to other healthcare professionals involved in the diagnosis and treatment of people with haematological cancers, and to junior doctors.

Cost:

£50 per day

Register:

www.royalmarsden.nhs.uk/studydays

Get in touch:

Conferenceteam@rmh.nhs.uk

020 7808 2921

Follow us:



Programme- Day 1:

This morning Elaine introduces the biology and genetics of haematological cancers. She also describes the basic principles that underlie many forms of treatment, such as antibody-based therapies, small molecules and cell-based treatments. This content provides an ideal starting point for day 2, in which Elaine delves into specific treatments for many different blood cancer types.

- 10:00 Welcome and Introductions**
- 10:10 Session 1—Biology and genetics of haematological cancers**
- Cell of origin of different cancer types
 - Types of DNA damage in haematological cancers
 - Consequences of common chromosome translocations and other mutations
 - Understanding the incidence of blood cancers in infants and children
- 10:45 Live Q&A**
- 10:55 Break/Sponsor Exhibition**
- 11:00 Session 2—Unique Properties of Haematological Cancers**
- Why most haematological cancers are derived from B cells
 - Important features of B cell cancers: indolent vs aggressive, TP53-mutated, IgHV mutated, B cell receptor signalling pathway activation
 - Importance of cell surface proteins and signalling pathways as the targets of treatments across various haematological cancers
 - Other targets; cell metabolism, epigenetics, cell survival, the immune microenvironment
- 11:35 Live Q&A**
- 11:45 Break/Sponsor Exhibition**
- 11:50 Session 3—Overview of treatment approaches**
- Types of targeted cancer treatment and their mechanisms of action: monoclonal antibodies, conjugated antibodies, BiTEs & bi-specific antibodies, small molecules, cell-based therapies
- 12:25 Live Q&A**

Please note that the content will be available for 30 days after the event online.

Sponsors:

The above sponsors provided funding for the study day, but they have had no input into the programme, selection of speakers or topics.